Table 1.
The ages and gender of participants in each study.
| Bediou et al. (2005b) |
Bediou et al. (2007b) |
Lachenal-Chevallet et al. (2006) |
Bediou et al. (2009a) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDD (N = 20) | SCZ-rem (N = 29) | CTL (N = 20) | SCZ-ON/OFF (N = 40) | SIB (N = 30) | CTL (N = 26) | PD-OFF/ON (N = 12) | CTL (N = 14) | AD (N = 10) | FTD (N = 10) | aMCI (N = 10) | CTL (N = 10) | |
| Age (years) | 39 (10) | 35 (10) | 26 (9) | 27 (6) | 31 (11) | 24 (3) | 61 (7) | 58 (8) | 72 (9) | 67 (7) | 73 (9) | 70 (6) |
| Gender (M/F) | 13/7 | 16/13 | 13/7 | 40/0 | 30/0 | 26/0 | 10/2 | 8/6 | 5/5 | 5/5 | 5/5 | 5/5 |
MDD, major depressive disorder; SCZ-rem, remitted schizophrenia; SCZ-ON/OFF, haloperidol; SIB, unaffected siblings of SCZ patients; PD, Parkinson’s disease (OFF/ON refer to l-DOPA treatment); AD, Alzheimer’s disease at mild dementia stage; FTD, frontotemporal dementia; aMCI, (clinical) amnestic mild cognitive impairment (i.e., prodromal AD); CTL, controls. M, male; F, female.